| nivolumab based treatment |
| nivolumab alone | nivolumab plus SoC |
mGC or mGEJC - 1st line (L1) | | |
mGC or mGEJC - L1 - all population | | |
mGC or mGEJC - L1 - HER2 neg/PDL1 positive 2 | | |
mGC or mGEJC - L1 - HER2 negative 1 | | |
mGC or mGEJC - L1 - HER2 positive | | |
mGC or mGEJC - L1 - PDL1 positive 4 | | |
mGC or mGEJC - 2nd Line (L2) | | |
mGC or mGEJC - L2 - all population 4 | | |
mGC or mGEJC - L2 - PDL1 positive 1 | | |
mGC or mGEJC - maintenance (M) | | |
mGC or mGEJC - M - HER2 negative 1 | | |
mGC or mGEJC - M - HER2 neg/PDL1 positive 1 | | |